Loading
Life sciences · Journal article
Biodesign Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Excessive intake of free sugars is a major modifiable risk factor for obesity, type 2 diabetes and cardiovascular disease, and it is a global public-health priority to reduce dietary sugar while preserving sensory quality. Referred to here as “healthy sugars”, the low-calorie monosaccharides D-allulose and D-tagatose combine sucrose-like sensory and bulking behavior with a distinct metabolic fate in humans and, for D-tagatose, with defence-inducing activity in plants. This review traces the evolution of sugar supply through four stages, from agricultural extraction of sucrose (Sugar 1.0) and enzymatic hydrolysis to high-fructose syrup (Sugar 2.0) to chemically synthesised high-intensity sweeteners (Sugar 3.0) and precision biomanufacturing of healthy sugars (Sugar 4.0). We review the molecular basis of healthy-sugar action in mammalian metabolic homeostasis and in plant sweet immunity, then compare manufacturing platforms, equilibrium-limited enzymatic epimerization, immobilized-enzyme and continuous-reactor processes, thermodynamically driven cell-free cascades, and cell-free CO 2 -to-hexose synthesis, through a consolidated cross-platform comparison of conversion, titer, yield, scalability and technology readiness. We then set out an amyloplast-targeted compartmentalised design for sugar-crop chassis, a distinct phosphorylated route for D-tagatose, and a climate-adaptive sugarcane, sugar beet, sorghum manufacturing crops. Finally we examine the conditions under which a plant-chassis route could offer cost or carbon advantages, comparing feedstock, energy, separation and carbon-balance considerations across platforms, and comparing the ingredient and biosafety requirements applying in the United States, the European Union and China. The plant-chassis route is presented throughout as a design proposal requiring crop-level validation, and the prerequisites for its projected advantages are stated explicitly.